🚀 VC round data is live in beta, check it out!
Achieve Life Sciences Valuation Multiples
Discover revenue and EBITDA valuation multiples for Achieve Life Sciences and similar public comparables like Lavipharm, Acepodia, Silence Therapeutics, Coherus Oncology and more.
Achieve Life Sciences Overview
About Achieve Life Sciences
Achieve Life Sciences Inc is a specialty pharmaceutical company committed to advancing cytisinicline as a widely available treatment option to help people battling nicotine addiction. It is an established smoking cessation treatment that has been approved and marketed in Central and Eastern Europe. Achieve's focus is to address the smoking health epidemic through the development and commercialization of cytisinicline. It has one operating segment, dedicated to the development and commercialization of cytisinicline for niceon.
Founded
1991
HQ
Employees
25
Website
Sectors
Financials (LTM)
EV
$208M
Achieve Life Sciences Financials
Achieve Life Sciences reported last 12-month revenue of $3M.
In the same LTM period, Achieve Life Sciences generated $3M in gross profit and had net loss of ($57M).
Revenue (LTM)
Achieve Life Sciences P&L
In the most recent fiscal year, Achieve Life Sciences reported revenue of — and EBITDA of ($37M).
Achieve Life Sciences expects next 12-month revenue of XXX and NTM EBITDA of XXX
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue | $3M | XXX | — | XXX | XXX | XXX |
| Gross Profit | $3M | XXX | — | XXX | XXX | XXX |
| Gross Margin | 85% | XXX | — | XXX | XXX | XXX |
| EBITDA | — | XXX | ($37M) | XXX | XXX | XXX |
| EBIT Margin | (1743%) | XXX | — | XXX | XXX | XXX |
| Net Profit | ($57M) | XXX | ($40M) | XXX | XXX | XXX |
| Net Margin | (1744%) | XXX | — | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
Achieve Life Sciences Stock Performance
Achieve Life Sciences has current market cap of $246M, and enterprise value of $208M.
Market Cap Evolution
Achieve Life Sciences' stock price is $4.62.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $208M | $246M | 0.0% | XXX | XXX | XXX | $-0.75 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialAchieve Life Sciences Valuation Multiples
Achieve Life Sciences trades at 63.5x EV/Revenue multiple, and (5.5x) EV/EBITDA.
EV / Revenue (LTM)
Achieve Life Sciences Financial Valuation Multiples
As of March 21, 2026, Achieve Life Sciences has market cap of $246M and EV of $208M.
Equity research analysts estimate Achieve Life Sciences' 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Achieve Life Sciences has a P/E ratio of (4.3x).
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $246M | XXX | $246M | XXX | XXX | XXX |
| EV (current) | $208M | XXX | $208M | XXX | XXX | XXX |
| EV/Revenue | 63.5x | XXX | — | XXX | XXX | XXX |
| EV/EBITDA | — | XXX | (5.5x) | XXX | XXX | XXX |
| EV/EBIT | (3.6x) | XXX | (5.3x) | XXX | XXX | XXX |
| EV/Gross Profit | 74.8x | XXX | — | XXX | XXX | XXX |
| P/E | (4.3x) | XXX | (6.2x) | XXX | XXX | XXX |
| EV/FCF | — | XXX | (7.0x) | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified Achieve Life Sciences Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.
Achieve Life Sciences Margins & Growth Rates
Achieve Life Sciences' revenue in the last 12 month grew by 1039%.
Achieve Life Sciences' revenue per employee in the last FY averaged $0.1M.
Achieve Life Sciences Operational Valuation Multiples
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 1039% | XXX | — | XXX | XXX | XXX |
| EBITDA Growth | — | XXX | 40% | XXX | XXX | XXX |
| Revenue per Employee | — | XXX | $0.1M | XXX | XXX | XXX |
| G&A Expenses to Revenue | 1080% | XXX | — | XXX | XXX | XXX |
| R&D Expenses to Revenue | 753% | XXX | — | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Achieve Life Sciences Public Comps
See public comps and valuation multiples for other Biopharmaceuticals comps.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| LTM | 2026E | 2027E | LTM | 2026E | 2027E | |
| Lavipharm | XXX | XXX | XXX | XXX | XXX | XXX |
| Acepodia | XXX | XXX | XXX | XXX | XXX | XXX |
| Silence Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| Coherus Oncology | XXX | XXX | XXX | XXX | XXX | XXX |
| OmniAb | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Achieve Life Sciences M&A Activity
Achieve Life Sciences acquired XXX companies to date.
Last acquisition by Achieve Life Sciences was on XXXXXXXX, XXXXX. Achieve Life Sciences acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Acquisitions by Achieve Life Sciences
| Acquired Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Get Verified M&A Valuation Multiples
Sign up to see revenue and EBITDA valuation multiples for 150K+ M&A deals.
Start Free TrialAchieve Life Sciences Investment Activity
Achieve Life Sciences invested in XXX companies to date.
Achieve Life Sciences made its latest investment on XXXXXXXX, XXXXX. Achieve Life Sciences invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Investments by Achieve Life Sciences
| Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout Achieve Life Sciences
| When was Achieve Life Sciences founded? | Achieve Life Sciences was founded in 1991. |
| Where is Achieve Life Sciences headquartered? | Achieve Life Sciences is headquartered in United States. |
| How many employees does Achieve Life Sciences have? | As of today, Achieve Life Sciences has over 25 employees. |
| Who is the CEO of Achieve Life Sciences? | Achieve Life Sciences' CEO is Richard Alistair Balfour Stewart. |
| Is Achieve Life Sciences publicly listed? | Yes, Achieve Life Sciences is a public company listed on Nasdaq. |
| What is the stock symbol of Achieve Life Sciences? | Achieve Life Sciences trades under ACHV ticker. |
| When did Achieve Life Sciences go public? | Achieve Life Sciences went public in 1995. |
| Who are competitors of Achieve Life Sciences? | Achieve Life Sciences main competitors are Lavipharm, Acepodia, Silence Therapeutics, Coherus Oncology. |
| What is the current market cap of Achieve Life Sciences? | Achieve Life Sciences' current market cap is $246M. |
| What is the current revenue of Achieve Life Sciences? | Achieve Life Sciences' last 12 months revenue is $3M. |
| What is the current revenue growth of Achieve Life Sciences? | Achieve Life Sciences revenue growth (NTM/LTM) is 1039%. |
| What is the current EV/Revenue multiple of Achieve Life Sciences? | Current revenue multiple of Achieve Life Sciences is 63.5x. |
| Is Achieve Life Sciences profitable? | No, Achieve Life Sciences is not profitable. |
| What is the current net income of Achieve Life Sciences? | Achieve Life Sciences' last 12 months net income is ($57M). |
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.